IDYA today
$32.72+$0.97 (+3.04%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourBullish
15 minStrong Bullish
5 minAscending Triangle
Daily trend turns up above $34.51
Key levels
Resistance$36.35
Resistance$34.51
Support$32.34
Support$30.45
Latest news & SEC filings
AnalystMizuho keeps Outperform rating on IDEAYA Biosciences, cuts price target to $39
AnalystCitigroup keeps Buy rating on IDEAYA Biosciences, lifts target to $66
AnalystRBC Capital Markets trims IDEAYA Biosciences target to $45
All IDYA news →About IDEAYA Biosciences
IDEAYA Biosciences is a clinical-stage biopharmaceutical company focused on precision medicine oncology. It discovers and develops targeted therapies for genetically defined cancers, with a pipeline that includes small molecule inhibitors and antibody-drug conjugates. Its lead candidate, darovasertib, is being developed for uveal melanoma, and it also has programs in synthetic lethality and DNA damage response. The company operates primarily in the United States and collaborates with partners for development and commercialization.
Based on the company's 10-K filed Feb 17, 2026.
Nasdaq · Healthcare
IDEAYA Biosciences, Inc. (IDYA)
What Is the Price Target for IDYA?
SEPT Low Target
$35.00
SEPT Mid Target
$51.50
SEPT High Target
$60.00
Analyst Consensus
$51.50
Is IDYA a Buy or Sell Right Now?
Thesis
- •Revenue growing 3024.4% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IDYA.
Start Free Trial →Is IDYA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$46.91
27
Moat Score
NONE
3/9
Piotroski Score
18.9
Altman Z-Score
What Is Smart Money Doing with IDYA?
Insider Signal
NEUTRAL
1 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Hata Yujiro S | director officer | Buy | 26,338 | $114K | Oct 6, 2026 |
| Hata Yujiro S | director officer | Sale | 25,538 | $955K | Oct 6, 2026 |
| Hata Yujiro S | director officer | Sale | 800 | $31K | Oct 6, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IDYA Growth Story
Revenue YoY
3024.4%
3yr Revenue CAGR
62.5%
EPS Growth YoY
61.9%
FCF Growth YoY
70.8%
Revenue Trend
ACCELERATING
Dark Pool Trades for IDYA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IDYA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:32 | $32.72 | 2,015 | $$66K | BUY |
| 19:27:21 | $32.43 | 1,100 | $$36K | MIDPOINT |
| 19:27:21 | $32.43 | 1,100 | $$36K | MIDPOINT |
| 19:26:42 | $32.43 | 1,100 | $$36K | BUY |
| 19:26:42 | $32.43 | 1,200 | $$39K | BUY |
5 dark pool trades shown · $$212K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for IDEAYA Biosciences, Inc. (IDYA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IDYA — frequently asked questions
What is IDYA stock price today?
IDEAYA Biosciences, Inc. (IDYA) is at $32.72, up 3.04% (+$0.97) at the Nov 11, 2026 close.
Why is IDYA stock moving today?
Latest IDYA news — Nov 10, 2026: Mizuho keeps Outperform rating on IDEAYA Biosciences, cuts price target to $39 · Nov 5, 2026: Citigroup keeps Buy rating on IDEAYA Biosciences, lifts target to $66
What is the IDYA price target?
The average analyst price target for IDYA is $51.50, ranging from $35 to $60, based on 8 analysts. Latest: Guggenheim maintains on Sep 9, 2026.
What do analysts rate IDYA?
Analyst ratings for IDYA: 0 Buy, 14 Hold, 0 Sell — consensus Hold.
Did IDYA beat earnings?
IDYA last reported on Nov 3, 2026: EPS -$1.05 vs -$1.18 expected — a beat of 11.0%.
Does IDYA pay a dividend?
IDYA does not currently pay a dividend.
What are IDYA support and resistance levels?
Support: $32.34, $30.45, $26.81. Resistance: $34.51, $36.35, $37.90.
What are insiders doing with IDYA?
Insider activity: NEUTRAL, 1 buys and 2 sells in the last 90 days.
What is the latest news on IDYA?
Nov 10, 2026: Mizuho keeps Outperform rating on IDEAYA Biosciences, cuts price target to $39 · Nov 5, 2026: Citigroup keeps Buy rating on IDEAYA Biosciences, lifts target to $66 · Nov 4, 2026: RBC Capital Markets trims IDEAYA Biosciences target to $45